What’s the story behind Synagis’s patents?
Synagis (palivizumab) is a monoclonal antibody that protects infants and high‑risk children from respiratory syncytial virus (RSV). The drug was first approved by the FDA in 1998, and its commercial protection has come from a series of patents covering the antibody itself, its manufacturing process, and related formulations.
The original patent covering the antibody (US 6,173,317) was filed in 2000 and expired in 2014. Subsequent patents on the formulation and production method extended protection, and several of those still remain active. As of 2023, the longest‑running patents relating to Synagis expire in the late 2020s, which keeps the product on the market without a fully generic competitor. [1][2]
When will Synagis become generic?
The core antibody patent expired 2014, but patents on the drug’s formulation and delivery devices are still in force. These secondary patents are set to expire between 2026 and 2030. Once all these patents lapse, a generic version could enter the market, provided it meets FDA biosimilar or generic standards.
At present, no generic manufacturer has been approved, so Synagis remains the sole commercial product until the final patents expire.
Which companies hold the remaining patents?
Roche, the current manufacturer of Synagis, holds the remaining key patents. The company also owns patents that cover the antibody’s affinity, stability, and specific dosing formulations. These patents form the basis of Roche’s market exclusivity and protect against generic entry.
Can a competitor develop a biosimilar?
Yes, but the competitor must navigate multiple regulatory hurdles. In the U.S., a biosimilar must demonstrate high similarity to the reference product, including safety, efficacy, and quality. The remaining patents on Synagis’s formulation mean a biosimilar developer would need to either wait until those patents expire or negotiate a licensing agreement with Roche.
What are the risks for generic developers?
Developers face patent litigation if they produce a product that infringes on Roche’s patents. Additionally, the FDA may refuse approval if the generic does not meet the stringent similarity criteria, which can be costly and time‑consuming.
How does the patent status affect pricing?
Because Synagis is still protected by active patents, Roche can maintain a premium price—$12,000 to $15,000 per dose for high‑risk infants in the U.S. Once the patents expire and generics enter, competition should drive prices down, though the high cost of antibody production may keep prices relatively high compared to small‑molecule drugs.
Are there any regulatory pathways for rapid entry of a similar product?
The FDA’s “interchangeability” pathway for biosimilars would allow a generic to be substituted at the prescriber’s discretion if it meets interchangeability criteria. However, this is distinct from a fully generic approval and requires additional data on safety and efficacy.
When do the last patents expire?
Patents that cover the formulation and delivery system are slated to expire between 2026 and 2030, depending on the exact claim and jurisdiction. The original antibody patent’s expiration in 2014 was a few years after the first commercial launch.
Will competition change Synagis’s market share?
Once the patents expire, new entrants will likely enter the market. Competition could lower prices and increase access, especially for families in lower‑income brackets who face high out‑of‑pocket costs. Roche’s marketing and distribution strength, however, may allow it to retain a significant share in the short term.
What’s the impact on patients?
Patients and insurers currently face high costs, which can limit access. Patents delay the availability of cheaper alternatives, but once generics or biosimilars are approved, drug prices should decrease, improving affordability and coverage.
Where can I find up‑to‑date patent information?
The U.S. Patent and Trademark Office (USPTO) database lists all active patents for palivizumab and related claims. The FDA’s drug label and the drug’s approval history also provide key dates for patent expiration.
Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020580s001lbl.pdf
[2] https://patents.google.com/patent/US6173317B2/en